Risk factors for poor prognosis of children with Mycoplasma pneumonia pneumonia complicated with atelectasis

doi:10.3969/j.issn.1004-583X.2021.02.011

Abstract

Abstract:

Objective To explore the risk factors for poor prognosis of children with Mycoplasma pneumoniae pneumonia(MPP) complicated with atelectasis. Methods The study involved 126 children with MPP complicated with atelectasis who were hospitalized in the hospital from January 2018 to January 2020. According to prognosis, 61 children with unhealed atelectasis were divided into observation group, and 65 children with healed atelectasis were put into control group. Enzyme-linked immunosorbent assay (ELISA) was used to measure interleukin-2(IL-2), IL-4, IL-6, IL-10, tumor necrosis factor α(TNF-α), C reactive protein(CRP) and interferon-γ(IFN-γ). Results The right middle lobe atelectasis accounted for 31.96% in children with MMP complicated with atelectasis, ranking the top place; and followed by right upper lobe atelectasis 23.71%; the age, treatment duration, lesion site, as well as serum IL-4, IL-6 and IL-10, CRP, and IFN-γ in observation group were higher than those in control group (P<0.05). Conclusion The serum IL-4, IL-6, IL-10 and IFN-γ are related to the poor prognosis of MPP complicated with atelectasis.

Key words: mycoplasma, pneumonia, atelectasis, prognosis, factor analysis, statistical

CLC Number:

R725.631

Li Ximei, Tang Yu, Gong Chenfang. Risk factors for poor prognosis of children with Mycoplasma pneumonia pneumonia complicated with atelectasis[J]. Clinical Focus, 2021, 36(2): 149-152.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.011

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I2/149

Figures/Tables 3

References 13

[1]	Gao M, Wang K, Yang M, et al. Transcriptome analysis of bronchoalveolar lavage fluid from children with Mycoplasma pneumoniae pneumonia reveals natural killer and T cell-proliferation responses[J]. Front Immunol, 2018,21(9):1403-1409.
[2]	Bao T, Ya TU. New research progress on pathogenesis of Mycoplasma pneumoniae pneumonia in children[J]. World Latest Medicine Information, 2019,28(11):641-646.
[3]	王秀琴. 小儿肺炎支原体肺炎的临床特点及诊治分析[J]. 山西医药杂志, 2018,47(10):1195-1196.
[4]	程红. 儿童肺炎支原体肺炎治疗的研究进展[J]. 承德医学院学报, 2018,35(3):73-75.
[5]	Shah SS. Mycoplasma pneumoniae// Principles and practice of pediatric infectious diseases[M]. New York: Springer US, 2018: 1023-1027.
[6]	Xu J, Shu L. Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2018,20(1):37-42.
[7]	高孟娜, 陈述英, 杨晓雯. 儿童肺炎支原体感染的流行病学特征分析[J]. 泰山医学院学报, 2018,39(4):385-387.
[8]	徐时芬, 吴超雄, 钟蒙蒙, 等. 不同年龄儿童肺炎支原体肺炎的临床特征[J]. 中华实用儿科临床杂志, 2018,33(22):1699-1702.
[9]	Zhu Y, Li C, Deng P, et al. Epidemiological investigation and analysis of Mycoplasma pneumoniae infection[J]. Nanoence Nanotech Letters, 2019,21(11):2416-2423.
[10]	刘燕茹, 艾涛, 樊映红, 等. 重症肺炎支原体肺炎临床特点分析及预后评价[J]. 中国妇幼健康研究, 2018,29(10):1303-1307.
[11]	黄飞燕, 刘春艳, 朱红枫. 基于血清细胞因子的PLS-DA模型对儿童肺炎支原体肺炎的诊断价值[J]. 实用医学杂志, 2018,34(1):87-89, 92.
[12]	付迎新, 张王梅, 李学勤. 肺炎支原体肺炎患儿免疫功能及炎性因子的变化研究[J]. 北京医学, 2018,40(7):657-660.
[13]	郭孝红, 胡玉杰, 李俊梅, 等. 儿童难治性肺炎支原体肺炎的临床特点及血清IL-4、IL-6、IL-10、IFN-γ的变化分析[J]. 现代生物医学进展, 2018,24(18):4768-4771.

肺部病变部位	例(%)
左上叶肺不张	19(19.58)
左下叶肺不张	20(20.62)
右上叶肺不张	23(23.71)
右中叶肺不张	31(31.96)
右下叶肺不张	4(4.12)
合计	97(100)

肺部病变部位	例(%)
左上叶肺不张	19(19.58)
左下叶肺不张	20(20.62)
右上叶肺不张	23(23.71)
右中叶肺不张	31(31.96)
右下叶肺不张	4(4.12)
合计	97(100)

组别	例数	性别(例)		年龄 (岁)	治疗时间 (d)	病变部位(例)		IL-2 (ng/L)	IL-4 (ng/L)	IL-6 (ng/L)	IL-10 (ng/L)	CRP (mg/L)	TNF-α (ng/L)	IFN-γ (ng/L)
组别	例数	男	女	年龄 (岁)	治疗时间 (d)	左	右	IL-2 (ng/L)	IL-4 (ng/L)	IL-6 (ng/L)	IL-10 (ng/L)	CRP (mg/L)	TNF-α (ng/L)	IFN-γ (ng/L)
对照组	35	21	14	5.13±1.14	3.58±0.87	12	23	3.69±1.16	3.11±1.52	21.27±3.24	5.93±1.22	31.25±2.06	2.81±0.43	13.24±1.35
观察组	31	18	13	6.79±1.03	5.27±0.91	11	20	4.13±1.21	6.32±1.43	39.42±3.13	9.64±1.24	43.17±2.14	2.82±0.31	36.14±1.27
χ²/t值		0.213		6.176	7.708	6.015		0.201	-2.116	-6.027	-4.471	-7.136	0.328	-11.41
P值		0.001		0.413	0.024	0.014		0.472	0.019	0.001	0.011	0.001	0.683	0.001

组别	例数	性别(例)		年龄 (岁)	治疗时间 (d)	病变部位(例)		IL-2 (ng/L)	IL-4 (ng/L)	IL-6 (ng/L)	IL-10 (ng/L)	CRP (mg/L)	TNF-α (ng/L)	IFN-γ (ng/L)
组别	例数	男	女	年龄 (岁)	治疗时间 (d)	左	右	IL-2 (ng/L)	IL-4 (ng/L)	IL-6 (ng/L)	IL-10 (ng/L)	CRP (mg/L)	TNF-α (ng/L)	IFN-γ (ng/L)
对照组	35	21	14	5.13±1.14	3.58±0.87	12	23	3.69±1.16	3.11±1.52	21.27±3.24	5.93±1.22	31.25±2.06	2.81±0.43	13.24±1.35
观察组	31	18	13	6.79±1.03	5.27±0.91	11	20	4.13±1.21	6.32±1.43	39.42±3.13	9.64±1.24	43.17±2.14	2.82±0.31	36.14±1.27
χ²/t值		0.213		6.176	7.708	6.015		0.201	-2.116	-6.027	-4.471	-7.136	0.328	-11.41
P值		0.001		0.413	0.024	0.014		0.472	0.019	0.001	0.011	0.001	0.683	0.001

变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
变量	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
年龄	1.687	0.603	8.647	0.003	5.796	1.642	18.845
治疗时间	0.657	0.151	22.048	0.001	1.989	1.409	2.497
病变部位	1.213	0.217	19.226	0.001	3.534	2.021	6.216
IL-4(ng/L)	1.376	0.178	6.291	0.021	1.856	1.014	3.242
IL-6(ng/L)	1.978	0.644	12.572	0.001	7.463	2.497	22.648
IL-10(ng/L)	1.273	0.219	20.437	0.001	4.482	2.114	7.429
CRP(mg/L)	0.557	0.132	21.144	0.001	2.165	1.284	5.316
IFN-γ(ng/L)	0.703	0.278	5.291	0.029	2.214	1.105	5.328